Advanced search
Publication Cover
Artificial Cells, Nanomedicine, and Biotechnology
An International Journal
Volume 47, 2019 - Issue 1
Submit an article Journal homepage
3,790
Views
25
CrossRef citations to date
0
Altmetric
Research Article

Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway

Qing-Feng Xianga Department of Hepatobiliary Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China;b Department of General Surgery, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, ChinaView further author information
,
Mei-Xiao Zhanc Zhuhai Interventional Medical Center, Zhuhai Precision Medicine Center, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, ChinaView further author information
,
Yong Lic Zhuhai Interventional Medical Center, Zhuhai Precision Medicine Center, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, ChinaView further author information
,
Hui Liangb Department of General Surgery, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, ChinaView further author information
,
Cong Hub Department of General Surgery, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, ChinaView further author information
,
Yao-Ming Huangb Department of General Surgery, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, ChinaView further author information
,
Jing Xiaoc Zhuhai Interventional Medical Center, Zhuhai Precision Medicine Center, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, ChinaView further author information
,
Xu Hec Zhuhai Interventional Medical Center, Zhuhai Precision Medicine Center, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, ChinaView further author information
,
Yong-Jie Xinc Zhuhai Interventional Medical Center, Zhuhai Precision Medicine Center, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, ChinaView further author information
,
Min-Shan Chena Department of Hepatobiliary Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaCorrespondence[email protected]
View further author information
&
Li-Gong Luc Zhuhai Interventional Medical Center, Zhuhai Precision Medicine Center, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University, Zhuhai, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 83-89 | Received 14 Sep 2018, Accepted 26 Oct 2018, Published online: 19 Jan 2019

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Wancheng Qiu, Yanhua Chang, Jing Liu, Xu Yang, Yan Yu, Jiajia Li, Qing Liang & Guangchun Sun. (2020) Identification of P-Rex1 in the Regulation of Liver Cancer Cell Proliferation and Migration via HGF/c-Met/Akt Pathway. OncoTargets and Therapy 13, pages 9481-9495.
Read now
Anne Noonan & Timothy M. Pawlik. (2019) Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. Expert Opinion on Investigational Drugs 28:11, pages 941-949.
Read now

Articles from other publishers (23)

Jingxiao Gu, Shanlei Bao, Reaoxian Akemuhan, Zhongzheng Jia, Yu Zhang & Chen Huang. (2023) Radiomics Based on Contrast-Enhanced CT for Recognizing c-Met-Positive Hepatocellular Carcinoma: a Noninvasive Approach to Predict the Outcome of Sorafenib Resistance. Molecular Imaging and Biology.
Crossref
Ningning Yan, Ziheng Zhang, Sanxing Guo, Shujing Shen & Xingya Li. (2023) Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report. Frontiers in Medicine 10.
Crossref
Kate Minoux, Guillaume Lassailly, Massih Ningarhari, Henri Lubret, Medhi El Amrani, Valérie Canva, Stéphanie Truant, Philippe Mathurin, Alexandre Louvet, Gilles Lebuffe, Odile Goria, Eric Nguyen-Khac, Emmanuel Boleslawski & Sebastien Dharancy. (2022) Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation. Transplant International 35.
Crossref
Youngjin Cho & Seyoung Park. (2022) Multivariate response regression with low-rank and generalized sparsity. Journal of the Korean Statistical Society 51:3, pages 847-867.
Crossref
Lingyu Li, Lin Cheng, Ri Sa, Xian Qiu & Libo Chen. (2022) Real-world insights into the efficacy and safety of tyrosine kinase inhibitors against thyroid cancers. Critical Reviews in Oncology/Hematology 172, pages 103624.
Crossref
Ruyue Xu, Xinkuang Liu, Amin Li, Li Song, Jiaojiao Liang, Jiafeng Gao & Xiaolong Tang. (2022) c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway. Journal of Molecular Medicine 100:4, pages 585-598.
Crossref
Rahul Kumar Vempati & Rama Rao Malla. 2022. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 63 80 .
Zefeng Liu, Jin Lu, He Fang, Jiyao Sheng, Mengying Cui, Yongsheng Yang, Bo Tang & Xuewen Zhang. (2021) m6A Modification-Mediated DUXAP8 Regulation of Malignant Phenotype and Chemotherapy Resistance of Hepatocellular Carcinoma Through miR-584-5p/MAPK1/ERK Pathway Axis. Frontiers in Cell and Developmental Biology 9.
Crossref
Shanshan Deng, Antonio Solinas & Diego F. Calvisi. (2021) Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models. Frontiers in Oncology 11.
Crossref
Xu Yang, Jing Liu, Qing Liang & Guangchun Sun. (2020) Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma. Fundamental & Clinical Pharmacology 35:4, pages 690-699.
Crossref
Xinyao Hu, Hua Zhu, Yang Shen, Xiaoyu Zhang, Xiaoqin He & Ximing Xu. (2021) The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma. Frontiers in Oncology 11.
Crossref
Fangfang Zhao, Guohe Feng, Junyao Zhu, Zhijun Su, Ruyi Guo, Jiangfu Liu, Huatang Zhang & Yongzhen Zhai. (2021) 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy. Anti-Cancer Drugs 32:4, pages 386-393.
Crossref
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters & Omidreza Firuzi. (2021) Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Critical Reviews in Oncology/Hematology 160, pages 103234.
Crossref
Yuta Myojin, Takahiro Kodama, Kazuki Maesaka, Daisuke Motooka, Yu Sato, Satoshi Tanaka, Yuichi Abe, Kazuyoshi Ohkawa, Eiji Mita, Yoshito Hayashi, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Ayumu Taguchi, Hidetoshi Eguchi & Tetsuo Takehara. (2021) ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. Clinical Cancer Research 27:4, pages 1150-1161.
Crossref
Fei Xiao, Hongyu Li, Zhongxue Feng, Luping Huang, Lingmiao Kong, Min Li, Denian Wang, Fei Liu, Zhijun Zhu, Yong’gang Wei & Wei Zhang. (2021) Intermedin facilitates hepatocellular carcinoma cell survival and invasion via ERK1/2-EGR1/DDIT3 signaling cascade. Scientific Reports 11:1.
Crossref
Ze-Long Liu, Jing-Hua Liu, Daniel Staiculescu & Jiang Chen. (2021) Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Therapeutic Advances in Medical Oncology 13, pages 175883592110180.
Crossref
Yeliz Yılmaz, Tuğçe Batur, Peyda Korhan, Mehmet Öztürk & Neşe Atabey. 2021. Liver Cancer in the Middle East. Liver Cancer in the Middle East 333 364 .
Jianqing Yu, George G. Chen & Paul B. S. Lai. (2020) Targeting hepatocyte growth factor/c‐mesenchymal–epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies. Medicinal Research Reviews 41:1, pages 507-524.
Crossref
Yizhen Jiang, Xiaoxuan Tu, Xiangying Zhang, Haihong Liao, Shuwen Han, Weiqin Jiang, Yi Zheng, Peng Zhao, Zhou Tong, Qihan Fu, Quan Qi, Junjun Shen, Liping Zhong, Yuefen Pan & Weijia Fang. (2020) Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. Supportive Care in Cancer 28:11, pages 5569-5579.
Crossref
Pei-Yi Chu, Shiao-Lin Tung, Kuo-Wang Tsai, Fang-Ping Shen & Shih-Hsuan Chan. (2020) Identification of the Novel Oncogenic Role of SAAL1 and Its Therapeutic Potential in Hepatocellular Carcinoma. Cancers 12:7, pages 1843.
Crossref
Chih-Ta Chen, Li-Zhu Liao, Ching-Hui Lu, Yung-Hsuan Huang, Yu-Kie Lin, Jung-Hsin Lin & Lu-Ping Chow. (2020) Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells. Experimental & Molecular Medicine 52:3, pages 497-513.
Crossref
Haiyu Wang, Benchen Rao, Jiamin Lou, Jianhao Li, Zhenguo Liu, Ang Li, Guangying Cui, Zhigang Ren & Zujiang Yu. (2020) The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology 8.
Crossref
Ling Wei, Xingwu Wang, Liyan Lv, Jibing Liu, Huaixin Xing, Yemei Song, Mengyu Xie, Tianshui Lei, Nasha Zhang & Ming Yang. (2019) The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Molecular Cancer 18:1.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.